发现了新型性SHP2抑制剂,使用了基于药的虚拟选,分子对接,分子动力学模拟和主要组件分析
Pooja Singh1, Vikas Kumar2, Keun Woo Lee3,4
1Division of Applied Life Science (BK21 Four), Plant Molecular Biology and Biotechnology Research Center (PMBBRC), Gyeongsang National University (GNU), 501 Jinju-daero, Jinju 52828, Republic of Korea.
Pharmaceuticals (Basel, Switzerland)
|July 27, 2024
概括
研究人员确定了三种新型化合物,这些化合物有望在各种癌症中选择性抑制SHP2 (一种蛋白质铁酸酶) 的全性标,并可能阻止瘤细胞的增殖.
科学领域:
- 生物化学 生物化学
- 分子生物学分子生物学
- 计算化学计算化学
背景情况:
- SHP2是一种细胞质非受体蛋白氨酸酸酶,在各种癌症中至关重要.
- 在SHP2-依赖性癌症中,SHP2是抑制瘤细胞增殖的潜在治疗标.
研究的目的:
- 确定用于癌症治疗的新型选择性SHP2全抑制剂.
- 通过计算选和验证潜在的候选药物,以SHP2为目标.
主要方法:
- 基于药解剂的虚拟选超过一百万种化合物.
- 分子对接,分子动力学 (MD) 模拟和MM/PBSA计算.
- 主要组件分析 (PCA) 和ADME预测为所选的命中.
主要成果:
- 确定了三个潜在的打击化合物 (Lig_1,Lig_6,Lig_14).
- MD模拟证实了击中蛋白质复合物的稳定性.
- 计算的结合自由能量表明与参考分子相比具有强大的抑制潜力.
结论:
- 已识别的化合物 (Lig_1,Lig_6,Lig_14) 是选择性SHP2全抑制的有希望的候选物.
- 这些化合物可以作为开发针对SHP2.2的新抗癌疗法的基础.
- 需要进一步的实验验证,以确认它们的有效性和安全性.
相关概念视频
Protein-protein Interfaces
12.5K
Many proteins form complexes to carry out their functions, making protein-protein interactions (PPIs) essential for an organism's survival. Most PPIs are stabilized by numerous weak noncovalent chemical forces. The physical shape of the interfaces determines the way two proteins interact. Many globular proteins have closely-matching shapes on their surfaces, which form a large number of weak bonds. Additionally, many PPIs occur between two helices or between a surface cleft and a...
12.5K
Ligand Binding and Linkage
4.8K
Allosteric proteins have more than one ligand binding site; the binding of a ligand to any of these sites influences the binding of ligands to the other sites. When a protein is allosteric, its binding sites are called coupled or linked. In the case of enzymes, the site that binds to the substrate is known as the active site and the other site is known as the regulatory site. When a ligand binds to the regulatory site, this leads to conformational changes in the protein that can influence...
4.8K
Allosteric Proteins-ATCase
5.7K
Binding sites linkages can regulate a protein's function. For example, enzyme activity is often regulated through a feedback mechanism where the end product of the biochemical process serves as an inhibitor.
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis...
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis...
5.7K


